AtaiBeckley (STU:B72) Valuation Rank


STU:B72 AtaiBeckley Inc STU:B72
51 GF Score
Price €3.45
GF Value €6.32
! 4 Warning Signs
View Full Analysis

What is AtaiBeckley Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

AtaiBeckley Valuation Rank Related Terms

STU:B72
51GF Score
AtaiBeckley Inc STU:B72
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AtaiBeckley (STU:B72) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued. The current stock price of €3.45 is trading 45.5% below its estimated GF Value™ of €6.32.

Key valuation signals for STU:B72:

  • Valuation Rank:
  • GF Value™: €6.32 vs. price of €3.45 (45.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtaiBeckley Business Description

Other Exchanges ATAI:USAB72:Germany
Address 250 West 34th Street, New York, NY, USA, 10119
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
51GF Score

Get the complete analysis for STU:B72

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.45
Price
€6.32
GF Value